Positive Xience V Results for Diabetics
A subset analysis of diabetic patients in the SPIRIT II Clinical trial of the XIENCE V Everolimus Eluting Stent System showed nearly identical rates of in-stent late loss at six months in diabetic patients as those observed in the overall study patient population, according to new results presented at TCT last week.
Abbott also presented new positive nine-month safety data from the SPIRIT II trial, which showed no additional occurrences of MACE (Major Adverse Cardiac Event) or stent thrombosis between six and nine months.
Late loss is a measure of the change in the vessel diameter between the time immediately following stent placement and at six months.
XIENCE V has received a CE mark in Europe and is currently an investigational device in the United States and Japan.
More like this
- SPIRIT Trial Proves Favorable for Abbott DES
- Abbott Submits XIENCE V Everolimus Eluting Coronary Stent System Application for FDA Approval
- Abbott Begins U.S. Study of XIENCE V Drug Eluting
- Trial Data Reveals XIENCE V Outperforms TAXUS Express2 in Reducing MACE at Two Years
- Abbott Submits XIENCE V Application for Approval in Japan